Drug Profile
GSK 2618960
Alternative Names: GSK-2618960Latest Information Update: 04 Jun 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 7 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sjogren's syndrome
- Discontinued Multiple sclerosis
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Sjogren's-syndrome in United Kingdom (IV, Injection)
- 13 Nov 2017 GlaxoSmithKline withdraws a phase II trial in Sjogren's syndrome (In the elderly, In adults) in United Kingdom for portfolio prioritisation (IV) (EudraCT2016-004258-14) (NCT03239600)
- 01 Sep 2015 GlaxoSmithKline completes a phase I trial in healthy volunteers in the UK (NCT02293161)